

Claims

In the claims, please amend the claims as follows:

1. – 10. (Canceled).

11. (Currently Amended) An inhalable solid pharmaceutical formulation comprising

(a) ~~an active ingredient substance susceptible to chemical interaction with lactose which active ingredient is selected from:~~
3-(4-[[6-((2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl) benzenesulfonamide;
3-(3-[[7-((2*R*)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl)-amino]heptyl]oxy)propyl)benzenesulfonamide;
4-[(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol and
4-[(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol,
or a pharmaceutically acceptable salt, solvate or physiologically acceptable derivative thereof;

(b) lactose and

(c) magnesium stearate.

12. (Previously Presented) An inhalable solid pharmaceutical formulation as claimed in claim 11 wherein the magnesium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

13. (Canceled).

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).

18. (Withdrawn) A method for treating asthma, chronic obstructive pulmonary disease (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in claim 11.

19. (Withdrawn and Currently Amended) A method of preparing the a solid pharmaceutical formulation of claim 11 ~~preparation~~ comprising combining in one or more steps: (a) 4-[(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof ~~an active ingredient substance susceptible to interaction with a carrier~~, (b) lactose ~~a carrier~~ and (c) magnesium stearate.

20. (Previously Presented) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

21. (Canceled).

22. (Canceled).

23. (Canceled).

24. (Canceled).

25. (Canceled).